Introduction: In recent years, the systemic treatment of patients with metastatic renal-cell carcinoma (mRCC) has undergone profound innovations, offering the availability of new drugs, and raising the bar of the survival expectation in this, previously, almost-always, incurable disease. The likeliness of reaching durable response and long-term survival is still closely linked to good clinical management and smart treatment sequencing, rather than to a single systemic treatment choice. Areas covered: We review all systemic therapeutic options currently available, describe the evidence behind the current options available for mRCC patient treatment, and provide our personal cues to support clinical decisions. Expert opinion: The IMDC classif...
Metastatic renal cell cancer (mRCC) management has undergone a paradigm shift in recent decades. The...
<p>The treatment of metastatic renal cell carcinoma (mRCC) has changed dramatically in the past deca...
Metastatic renal cell cancer (mRCC) management has undergone a paradigm shift in recent decades. The...
Targeted agents have substantially improved outcomes in metastatic clear cell renal cell carcinoma. ...
The treatment paradigm in renal cell carcinoma (RCC) is rapidly changing. The incidental finding of ...
BACKGROUND: Several TTs are available to treat mRCC; however, the optimal sequence of therapy remain...
The therapeutic landscape for metastatic renal cell carcinoma has rapidly evolved over the years, an...
Introduction: Over the past decade metastatic renal cell carcinoma (RCC) treatment landscape has dra...
Purpose: Current systemic treatment of targeted therapies, namely the vascular endothelial growth fa...
Introduction: Over the past decade metastatic renal cell carcinoma (RCC) treatment landscape has dra...
The treatment of metastatic renal cell carcinoma (mRCC) has changed dramatically in the past decade....
Renal cell carcinoma (RCC), a common malignancy worldwide, affects 1200 new patients yearly in Swede...
The treatment of metastatic renal cell carcinoma (mRCC) has changed dramatically in the past decade....
Renal cell carcinoma (RCC), a common malignancy worldwide, affects 1200 new patients yearly in Swede...
The treatment of metastatic renal cell carcinoma (mRCC) has changed dramatically in the past decade....
Metastatic renal cell cancer (mRCC) management has undergone a paradigm shift in recent decades. The...
<p>The treatment of metastatic renal cell carcinoma (mRCC) has changed dramatically in the past deca...
Metastatic renal cell cancer (mRCC) management has undergone a paradigm shift in recent decades. The...
Targeted agents have substantially improved outcomes in metastatic clear cell renal cell carcinoma. ...
The treatment paradigm in renal cell carcinoma (RCC) is rapidly changing. The incidental finding of ...
BACKGROUND: Several TTs are available to treat mRCC; however, the optimal sequence of therapy remain...
The therapeutic landscape for metastatic renal cell carcinoma has rapidly evolved over the years, an...
Introduction: Over the past decade metastatic renal cell carcinoma (RCC) treatment landscape has dra...
Purpose: Current systemic treatment of targeted therapies, namely the vascular endothelial growth fa...
Introduction: Over the past decade metastatic renal cell carcinoma (RCC) treatment landscape has dra...
The treatment of metastatic renal cell carcinoma (mRCC) has changed dramatically in the past decade....
Renal cell carcinoma (RCC), a common malignancy worldwide, affects 1200 new patients yearly in Swede...
The treatment of metastatic renal cell carcinoma (mRCC) has changed dramatically in the past decade....
Renal cell carcinoma (RCC), a common malignancy worldwide, affects 1200 new patients yearly in Swede...
The treatment of metastatic renal cell carcinoma (mRCC) has changed dramatically in the past decade....
Metastatic renal cell cancer (mRCC) management has undergone a paradigm shift in recent decades. The...
<p>The treatment of metastatic renal cell carcinoma (mRCC) has changed dramatically in the past deca...
Metastatic renal cell cancer (mRCC) management has undergone a paradigm shift in recent decades. The...